Novakand Pharma AB (publ)
SSTO:NOVKANShare Statistics
As of December 31, 2025, Novakand Pharma AB (publ) has 121.19M shares outstanding.
| Shares Outstanding | 121.19M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | -0.04 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | -0.63 |
| P/OCF Ratio | -0.63 |
Financial Position
As of December 31, 2025, Novakand Pharma AB (publ) maintains a current ratio of 10.03, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.03 |
| Quick Ratio | 9.63 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -112.94, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -112.94 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -159.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -159.81 |
Stock Splits
Novakand Pharma AB (publ)'s most recent stock split took place on February 29, 2024 with a 1000:1023 split ratio.
| Last Split Date | 2/29/2024 |
| Split Ratio | 1000:1023 |
Scores
As of December 31, 2025, Novakand Pharma AB (publ) has an Altman Z-Score of -36.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -36.05 |